ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
Titel:
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
Auteur:
Vermeire, Severine Sands, Bruce E Tilg, Herbert Tulassay, Zsolt Kempinski, Radoslaw Danese, Silvio Bunganič, Ivan Nitcheu, Josianne Santo, Julien Scherrer, Didier Biguenet, Sophie Ehrlich, Hartmut J Steens, Jean-Marc Gineste, Paul Sandborn, William J